Blinatumomab and inotuzumab for B cell precursor acute lymphoblastic leukaemia in children: a retrospective study from the Leukemia Working Group of the Spanish Society of Pediatric Hematology and Oncology (SEHOP)
Por:
Fuster JL, Molinos-Quintana A, Fuentes C, Fernández JM, Velasco P, Pascual T, Rives-Solà S, Dapena JL, Sisinni L, López-Godino O, Palomo P, Villa-Alcázar M, Bautista F, González-Vicent M, López-Duarte M, García-Morín M, Ramos-Elbal E and Ramírez M
Publicada:
1 sep 2020
Ahead of Print:
1 abr 2020
Categoría:
Hematology
Resumen:
Blinatumomab and inotuzumab ozogamycin represent promising alternatives to conventional chemotherapy in acute lymphoblastic leukaemia (ALL). We analysed data from 29 children with ALL treated under compassionate use with blinatumomab, inotuzumab or both. The complete remission (CR) rate in a heavily pretreated population with overt relapse was 47 center dot 6%. At earlier stages (first/second CR), both antibodies represented a useful tool to reduce minimal residual disease, and/or avoid further toxic chemotherapy until stem cell transplantation. Six patients developed grade 3 reversible non-haematological toxicity. The 12-month overall survival and event-free survival rates were 50 center dot 8 +/- 26 center dot 4% and 38 center dot 9 +/- 25 center dot 3% with blinatumomab, 45 center dot 8 +/- 26% and 27 center dot 5 +/- 25% with inotuzumab.
Filiaciones:
Fuster JL:
Pediatric Oncology and Haematology Department, Hospital Clínico Universitario Virgen de la Arrixaca, Instituto Murciano de Investigación Biosanitaria (IMIB), Murcia, Spain
Molinos-Quintana A:
Department of Hematology, Pediatric Hematology, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina (IBIS/CISC), Sevilla, Spain
Fuentes C:
Pediatric Oncology and Haematology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain
Fernández JM:
Pediatric Oncology and Haematology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain
Velasco P:
Pediatric Oncology and Haematology Department, Hospital Universitario Vall d'Hebron, Barcelona, Spain
Pascual T:
Pediatric Hematology Unit, Hematology Department, Hospital Regional Universitario de Málaga, Málaga, Spain
Rives-Solà S:
Hematology Department, Hospital San Joan de Déu, Institut de Reserca Sant Joan de Déu, Barcelona, Spain
Dapena JL:
Hematology Department, Hospital San Joan de Déu, Institut de Reserca Sant Joan de Déu, Barcelona, Spain
Sisinni L:
Pediatric Hematology, Oncology and Hematopoietic Stem Cell Transplantation Unit, Santa Creu i Sant Pau Hospital, Barcelona, Spain
López-Godino O:
Hematology and Oncology Department, Centro Regional de Hemodonación, Hospital Universitario Morales Meseguer, Universidad de Murcia, Instituto Murciano de Investigación Biosanitaria (IMIB-Arrixaca), CIBERER, Murcia, Spain
Palomo P:
Pediatric Hematology Unit, Hematology Department., Hospital Universitario Central de Asturias, Oviedo, Spain
Villa-Alcázar M:
Hematology and Oncology Department, Hospital Universitario HM Montepríncipe, HM/CIOCC, Madrid, Spain
Bautista F:
Pediatric Oncology, Haematology and Stem Cell Transplantation Department, Hospital Niño Jesús, Madrid, Spain
González-Vicent M:
Pediatric Oncology, Haematology and Stem Cell Transplantation Department, Hospital Niño Jesús, Madrid, Spain
López-Duarte M:
Pediatric Hematology Unit, Hematology Department, Hospital de Valdecilla, Santander, Spain
García-Morín M:
Pediatric Oncology and Haematology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain
Ramos-Elbal E:
Pediatric Oncology and Haematology Department, Hospital Clínico Universitario Virgen de la Arrixaca, Instituto Murciano de Investigación Biosanitaria (IMIB), Murcia, Spain
Ramírez M:
Pediatric Oncology, Haematology and Stem Cell Transplantation Department, Hospital Niño Jesús, Madrid, Spain
Bronze
|